Vertex Pharmaceuticals (NasdaqGS:VRTX) saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Leslie A. Parker, MSN, RNC, NNP; Sheryl J. Montrowl, MSN, RNC, NNP Infants with CNS disease present with acute symptoms of meningitis, including a bulging fontanel ...

There are a bunch of different categories with various actions that you can take. Some students are chosen to give presentations, which you can then rate as well. Within the game, you can level up as ...